ERBB2 and cancer: Even more to the point, six of the top 10 most-cited papers were composed by professor Bardelli A. The leading two of his highly cited articles, “Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer” and “A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer”, were published in Nature (IF=49.96) and Cancer Discovery (IF=39.40), respectively.